-The Indian Express West Bengal is not new to chit fund scams. What is unique to the Saradha Group scandal is how it targeted the poorest and the most marginalised, leaving them on the verge of devastation. From 17-year-old agents who raised money from depositors to 50-year-old widows who invested money, the Saradha Group didn't discriminate in roping them in. Since the house of cards started collapsing, two agents and two...
More »SEARCH RESULT
Total Matching Records found : 1152
Saradha chit fund scam: West Bengal, Northeast hot-bed of investment frauds; NRIs major target
-PTI Amid a raging controversy over alleged cheating of gullible investors by Saradha group, the regulators have found that West Bengal and North-Eastern states have become a hot-bed of such frauds and NRIs from these regions account for a large chunk of defrauded people. While the Centre has announced an SFIO ( Serious Fraud Investigation Office) probe into the affairs of Kolkata-based Saradha group and other such entities across the country,...
More »Land lease is an idea whose time has come-NC Saxena
-The Business Standard It will make the coercive powers of the land acquisition law irrelevant, though including it in the central Bill would be unconstitutional The proposal to amend the central Land Acquisition Bill to provide for leasing of land rather than acquiring it is just not constitutionally feasible. Land is a state subject and the Centre cannot legislate on leasing at all. But as an idea it is great and should...
More »Twin SC rulings provide relief for natural resources sector -Neha Sethi and Ruchira Singh
-Live Mint Vedanta can mine bauxite in Orissa with gram sabha nod, some Karnataka iron ore mines to reopen Two key judgements passed by the Supreme Court on Thursday bode well for India's troubled natural resources sector, keeping alive Vedanta Resources Plc's hopes of mining bauxite in Orissa and promising an alleviation of raw material shortages at steel makers by partly lifting a ban on iron ore mining in Karnataka. The country's top...
More »SC’s Novartis judgement renews focus on accessible medicine
The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...
More »
